1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
AssigneeNeurogen Corporation
InventorsAndrew Thurkauf, Xi Chen
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable addition salts thereof wherein: R.sub.1 is halogen or C.sub.1 -C.sub.4 alkyl; and R.sub.2 and R.sub.3 are the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, alkylthio, hydroxy, amino, mono(C.sub.1 -C.sub.4)alkylamino, di(C.sub.1 -C.sub.4)alkylamino, or R.sub.2 and R.sub.3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.
Claims26
A compound of the formula:
- ##STR12## or the pharmaceutically acceptable salts thereof wherein:
- R.sub.1 is C.sub.1 -C.sub.4 alkyl or halogen.
A compound of the formula:
- ##STR13## or the pharmaceutically acceptable salts thereof wherein:
- R.sub.1 is chlorine or fluorine;
- and ##STR14## is selected from the group consisting of:
- ##STR15##
A compound of the formula:
- ##STR18## or the pharmaceutically acceptable salts thereof wherein:
- R.sub.1 is methyl;
- and ##STR19## represents 3,4-dichlorophenyl, 4-methoxyphenyl, or 2-methoxyphenyl.
Dependencies are inferred from the claim text.